Genmab A/S
Kalvebod Brygge 43
DK-1560 Copenhagen V
Denmark
Tel. +45 7020 2728
www.genmab.com
CVR no. 2102 3884

March 09, 2021

Dear Shareholder,

Please find enclosed an invitation to attend Genmab A/S' 2021 Virtual Annual General Meeting to be held on

Tuesday, April 13, 2021 at 14:00 PM CEST

Due to COVID-19, the Annual General Meeting is held as a fully virtual meeting. You will be able to participate via our website and we encourage you to exercise your rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.

The past year was like no other in the history of Genmab. I am proud to say that as an organization, we not only rose to meet the global challenges presented by the COVID-19 pandemic in 2020; we made tremendous strides in our evolution into a leading, fully integrated innovation powerhouse, and are closer than ever to achieving our 2025 Vision of transforming cancer treatment.

We reached an inflection point in 2020, created by a series of key events, including our broad oncology collaboration with AbbVie. The collaboration with AbbVie is a landmark achievement for Genmab that puts us on a path to accelerate, broaden and maximize the development of some of our promising bispecific antibody products, with the ultimate goal of bringing new potential medicines much faster to cancer patients. A key component of our collaboration with AbbVie is the development of epcoritamab. The first patient was treated with epcoritamab in 2018, and by the end of 2020 we announced the first Phase 3 study. During 2020 we reported very favorable Phase 2 innovaTV 204 study results in metastatic cervical cancer, and we along with Seagen, filed our first Biologics License Application (BLA) for tisotumab vedotin in the first quarter of 2021. We were also extremely pleased to present the first clinical data for DuoBody-PD-L1x4-1BB, one of our programs in development with BioNTech, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting.

DARZALEX® has already revolutionized the treatment of multiple myeloma, and in 2020 it became the first and only subcutaneously administered CD38 antibody approved in the world. In addition to DARZALEX®, Subcutaneous (SubQ) ofatumumab, which is being developed and marketed by Novartis, was approved as Kesimpta®, in the U.S. for relapsing forms of multiple sclerosis (RMS). A third Genmab-created antibody was approved in 2020, with the U.S. Food and Drug Administration (U.S. FDA) approval of TEPEZZA® (teprotumumab), developed and commercialized by Horizon Therapeutics, for thyroid eye disease (TED). TEPEZZA® is the first and only U.S. FDA approved medicine for the treatment of TED, and it has had an incredibly successful launch. Finally, it is also worth noting that, Janssen submitted applications for approval for amivantamab in both the U.S. and in Europe in December. These are the first regulatory submissions for a product candidate that was created using Genmab's proprietary DuoBody® technology platform.

I believe that 2020 was a turning point for Genmab, with events that turbocharged our evolution into a fully integrated biotech innovation powerhouse. I look forward to further describing our progress at the Virtual 2021 Annual General Meeting. If you are unable to participate, I encourage you to return the enclosed proxy, or to vote by post. I would like to take this opportunity to thank you for your continued support.

Sincerely yours,

Jan van de Winkel, Ph.D.
President & Chief Executive Officer